BRPI0518198A - métodos de interrupção melhorados para processos de inativação de células hemácias - Google Patents

métodos de interrupção melhorados para processos de inativação de células hemácias

Info

Publication number
BRPI0518198A
BRPI0518198A BRPI0518198-4A BRPI0518198A BRPI0518198A BR PI0518198 A BRPI0518198 A BR PI0518198A BR PI0518198 A BRPI0518198 A BR PI0518198A BR PI0518198 A BRPI0518198 A BR PI0518198A
Authority
BR
Brazil
Prior art keywords
methods
red blood
blood cell
improved
improved interruption
Prior art date
Application number
BRPI0518198-4A
Other languages
English (en)
Inventor
Adonis Stassinopoulos
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Publication of BRPI0518198A publication Critical patent/BRPI0518198A/pt
Publication of BRPI0518198B1 publication Critical patent/BRPI0518198B1/pt
Publication of BRPI0518198B8 publication Critical patent/BRPI0518198B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/124—Disinfecting agents, e.g. antimicrobials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MéTODOS DE INTERRUPçãO MELHORADOS PARA PROCESSOS DE INATIVAçãO DE CéLULAS HEMáCIAS. A presente invenção refere-se a métodos para a interrupção melhorada de reações secundárias indesejáveis no tratamento de uma composições de células hemácias que são fornecidos com um composto inativador de patógeno compreendendo um ligante que se liga a ácidos nucléícos e um grupo funcional o qual é, ou o qual é capaz de formar um grupo eletrofílíco. Em algumas modalidades, os métodos melhorados usam uma concentração adequadamente alta de supressor que compreende um grupo funcional nucleofilico que é capaz de reagir covalentemente com o grupo eletrofilíco, em que o tratamento ocorre em uma faixa de pH desejada para fornecer supressão suficiente. Supressores preferidos para uso em alguns dos métodos incluem tióis, tais como glutationa, os quais tenham sido adequadamente neu- tralizados de forma que a adição a uma composição de células hemácias resulte na concentração desejada de supressor em uma faixa de pH desejável de 6,8 a 8,5.
BRPI0518198A 2004-10-29 2005-10-31 método ex vivo para tratar uma composição de células hemácias para inativar um patógeno, se presente, bem como composição e kit BRPI0518198B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62317704P 2004-10-29 2004-10-29
US60/623,177 2004-10-29
PCT/US2005/039392 WO2006050328A1 (en) 2004-10-29 2005-10-31 Improved quenching methods for red blood cell inactivation process

Publications (3)

Publication Number Publication Date
BRPI0518198A true BRPI0518198A (pt) 2008-11-04
BRPI0518198B1 BRPI0518198B1 (pt) 2018-11-21
BRPI0518198B8 BRPI0518198B8 (pt) 2021-06-22

Family

ID=35789172

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518198A BRPI0518198B8 (pt) 2004-10-29 2005-10-31 método ex vivo para tratar uma composição de células hemácias para inativar um patógeno, se presente, bem como composição e kit

Country Status (12)

Country Link
US (1) US7655392B2 (pt)
EP (1) EP1838355B1 (pt)
JP (3) JP5346468B2 (pt)
CN (2) CN101094692A (pt)
AU (2) AU2005302256B2 (pt)
BR (1) BRPI0518198B8 (pt)
CA (1) CA2585621C (pt)
DK (1) DK1838355T3 (pt)
ES (1) ES2429088T3 (pt)
PL (1) PL1838355T3 (pt)
PT (1) PT1838355E (pt)
WO (1) WO2006050328A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826521T2 (de) * 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
CN101094692A (zh) 2004-10-29 2007-12-26 塞鲁斯公司 用于红细胞灭活过程的改进的猝灭方法
SG189745A1 (en) * 2008-04-09 2013-05-31 Cerus Corp Improved quenching methods for red blood cell pathogen inactivation
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
WO2014183134A1 (en) * 2013-05-10 2014-11-13 President And Fellows Of Harvard College Solutions for red blood cells
WO2016014854A1 (en) 2014-07-23 2016-01-28 Cerus Corporation Methods for preparing platelet products
MX2017011595A (es) 2015-03-10 2018-06-15 New Health Sciences Inc Kits, dispositivos descartables para reducir el oxígeno y métodos para usarlos.
AU2016253005B2 (en) 2015-04-23 2020-07-09 Hemanext Inc. Anaerobic blood storage containers
BR122021024421B1 (pt) 2015-05-18 2022-05-03 Hemanext Inc Usos de um produto de sangue total armazenado reduzido de oxigênio com plaquetas
WO2016210374A1 (en) 2015-06-26 2016-12-29 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
EP3364986B1 (en) 2015-10-23 2023-12-13 Cerus Corporation Pathogen-inactivated cryo-poor plasma and methods of use thereof
WO2017205590A2 (en) * 2016-05-27 2017-11-30 New Health Sciences, Inc. Anaerobic blood storage and pathogen inactivation method
EA201991506A1 (ru) 2016-12-23 2020-01-23 Сирус Корпорейшн Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
WO2018125994A1 (en) * 2016-12-31 2018-07-05 Cerus Corporation Compositions and methods for preparation of red blood cells
CN110573169B (zh) 2017-03-03 2024-10-01 塞鲁斯公司 制备病原体灭活的血小板组合物的试剂盒和方法
SG11202002438TA (en) 2017-09-20 2020-04-29 Cerus Corp Compositions and methods for pathogen inactivation of platelets
CN116571191A (zh) 2017-12-29 2023-08-11 塞鲁斯公司 用于处理生物流体的系统和方法
AU2019310577B2 (en) * 2018-07-27 2025-05-22 New York Blood Center, Inc. Method for pathogens, microorganisms, and parasites inactivation
CN119701114A (zh) * 2018-09-20 2025-03-28 塞鲁斯公司 用于制备病原体灭活的全血的方法和套件
JP7571063B2 (ja) 2019-06-22 2024-10-22 シーラス コーポレイション 生物学的流体の処理を実施するシステム及び方法
CN114173842A (zh) 2019-06-22 2022-03-11 塞鲁斯公司 生物流体处理系统
WO2020264421A1 (en) 2019-06-28 2020-12-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2402665A (en) 1942-11-12 1946-06-25 Du Pont Chemical process
IT1093275B (it) 1978-01-26 1985-07-19 Snam Progetti Composizione adatta alla purificazione del sangue e suoi impieghi
US4337269A (en) 1979-07-23 1982-06-29 Sutton Laboratories, Inc. Preservative compositions
US4727027A (en) 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4748120A (en) 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US5281579A (en) 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
US4971760A (en) 1986-03-10 1990-11-20 University Of Southern California Novel method for disinfecting red blood cells, blood platelets, blood plasma, and optical corneas and sclerae
US4944920A (en) 1986-08-01 1990-07-31 University Of Southern California Novel method to treat blood
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5094960A (en) 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
US5055485A (en) 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5587490A (en) 1990-04-16 1996-12-24 Credit Managers Association Of California Method of inactivation of viral and bacterial blood contaminants
US5658722A (en) 1990-05-15 1997-08-19 New York Blood Center, Inc. Process for the sterilization of biological compositions using UVA1 irradiation
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5120649A (en) 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5753258A (en) 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
GB9218581D0 (en) 1992-09-02 1992-10-14 Pall Corp Removal of unwanted fluids from processed blood products
JPH09500015A (ja) 1993-06-23 1997-01-07 ニューヨーク ブラッド センター，インコーポレイティド 血液のウィルス不活性化のためのシステム
US5591350A (en) 1994-04-15 1997-01-07 Pall Corporation Iodine disinfection method using a gaseous iodine treated porous medium
SE9402472L (sv) 1994-07-13 1996-01-14 Forskarpatent I Linkoeping Ab Modifierade ytor
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5660731A (en) 1994-11-08 1997-08-26 Pall Corporation Filter for separating photoactive agent
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US5637451A (en) 1995-03-29 1997-06-10 New York Blood Center, Inc. Photodynamic treatment of red blood cells with phthalocyanines and red light at higher light fluence rates is protective of red blood cells
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
ES2337852T3 (es) 1995-06-07 2010-04-29 Cerus Corporation Metodos y dispositivos para la eliminacion de psoralenos de productos sanguineos.
US6544727B1 (en) 1995-06-07 2003-04-08 Cerus Corporation Methods and devices for the removal of psoralens from blood products
WO1996039818A1 (en) 1995-06-07 1996-12-19 Cerus Corporation Treating red blood cell solutions with anti-viral agents
EP0830057A4 (en) 1995-06-07 2000-07-12 Baxter Int METHOD FOR INACTIVATING VIRAL AND BACTERIAL BLOOD IMPURITIES
US20020192632A1 (en) 1995-06-07 2002-12-19 Hei Derek J. Method and devices for the removal of psoralens from blood products
CA2198085A1 (en) 1995-06-29 1997-01-23 Hemasure, Inc. Inactivation of pathogens using hydroxymethylamines
US6136586A (en) 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US6114108A (en) 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
EP0881874B1 (en) 1995-11-06 2003-04-02 New York Blood Center, Inc. Viral inactivation treatment of red blood cells using phthalocyanines and red light
WO1997018844A1 (en) 1995-11-21 1997-05-29 Pall Corporation Inactivation method and system in biological fluids
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US6093725A (en) 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US20010009756A1 (en) 1998-01-06 2001-07-26 Derek Hei Flow devices for the reduction of compounds from biological compositions and methods of use
CA2276532C (en) 1997-01-06 2008-06-17 Cerus Corporation Frangible compounds for pathogen inactivation
US20010018179A1 (en) 1998-01-06 2001-08-30 Derek J. Hei Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
DE69826521T2 (de) 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
US6277337B1 (en) * 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
WO2001091775A2 (en) * 2000-05-31 2001-12-06 Cerus Corporation Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
CN100417325C (zh) * 2000-11-04 2008-09-10 王祥文 卫生灭菌消毒剂
CA2434256A1 (en) * 2000-12-21 2003-07-31 David Cook Methods for inactivation of pathogens in biological materials
CN1186099C (zh) * 2001-12-13 2005-01-26 孙岩军 麻醉机呼吸回路清洗消毒的方法及其操作步骤
CN101094692A (zh) 2004-10-29 2007-12-26 塞鲁斯公司 用于红细胞灭活过程的改进的猝灭方法

Also Published As

Publication number Publication date
EP1838355A1 (en) 2007-10-03
US7655392B2 (en) 2010-02-02
DK1838355T3 (da) 2013-10-28
AU2005302256A1 (en) 2006-05-11
JP5346468B2 (ja) 2013-11-20
CN101094692A (zh) 2007-12-26
EP1838355B1 (en) 2013-08-14
AU2011201554B2 (en) 2012-04-26
CA2585621A1 (en) 2006-05-11
CA2585621C (en) 2015-12-15
BRPI0518198B8 (pt) 2021-06-22
HK1109594A1 (en) 2008-06-13
JP2013256537A (ja) 2013-12-26
CN103961731B (zh) 2017-01-18
AU2011201554A1 (en) 2011-04-28
PL1838355T3 (pl) 2014-01-31
WO2006050328A1 (en) 2006-05-11
US20060115466A1 (en) 2006-06-01
BRPI0518198B1 (pt) 2018-11-21
ES2429088T3 (es) 2013-11-13
CN103961731A (zh) 2014-08-06
PT1838355E (pt) 2013-11-07
AU2005302256B2 (en) 2011-01-20
JP2012107068A (ja) 2012-06-07
JP2008518952A (ja) 2008-06-05
JP5718840B2 (ja) 2015-05-13

Similar Documents

Publication Publication Date Title
BRPI0518198B8 (pt) método ex vivo para tratar uma composição de células hemácias para inativar um patógeno, se presente, bem como composição e kit
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
BRPI0510666A (pt) compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
ATE478861T1 (de) Multizyklische verbindung und verwendungsverfahren
IL180722A0 (en) Thienopyrimidine derivatives and pharmaceutical compositions containing the same
BRPI0909044B8 (pt) anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
BRPI0410037A (pt) inibidores da fosfatidilinositol 3-cinase
BRPI0607306A2 (pt) derivados de quinoxalina como agentes anti-tumor
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
BRPI0508390B8 (pt) uso de um anticorpo antagonista anti-ngf, bem como kit e composição farmacêutica para tratamento de dor de câncer de osso
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
GEP20125643B (en) Aurora kinase modulators and method of using same
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
WO2002096867A3 (en) Inhibitors of protein kinase for the treatment of disease
BRPI0718803B8 (pt) composto para inibir a progressão mitótica, composição farmacêutica e método in vitro para inibir a atividade de aurora cinase em uma célula
BRPI0511479A (pt) molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
MX2009010517A (es) Moduladores de cinasa aurora y metodos de uso.
ATE395905T1 (de) Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
WO2008042282A3 (en) Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
BR0011738A (pt) Derivados de benzeno, processo para a preparação dos mesmos e composições farmacêuticas que os contêm

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2694 DE 23-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.